Penny Stock Bounce Watch (IVP, ASLN, UCAR, WINT, SEEL)

Welcome to the frontier of potential gains. Let's explore five intriguing penny stock opportunities potentially poised for a rebound.

Inspire Veterinary Partners Inc. (NASDAQ: IVP) - The company closed last week down 9% at $.39. In early December, they entered into a $30 million stock purchase agreement with Tumim Stone Capital LLC. Consistent with certain applicable Nasdaq rules, Inspire may not issue to the Investor more than 1,214,293 shares of its Class A Common Stock (the “Exchange Cap”) under the Purchase Agreement, which number of shares is equal to 19.99% of the shares of the Company’s Class A Common Stock issued and outstanding immediately prior to the execution of the Purchase Agreement, unless Inspire obtains stockholder approval to issue shares of its Class A Common Stock in excess of such limit in accordance with applicable rules of Nasdaq or any other applicable national stock exchange. The Exchange Cap will not apply to the extent that and for so long as the average price of all shares of Class A Common Stock purchased pursuant to the Purchase Agreement is equal to or greater than $0.4954, which was the official closing price of the Class A Common Stock on Nasdaq on the date of signing the Purchase Agreement. Additionally, in Q4 2023 and beyond, the company plans strategic acquisitions for general practice and specialty hospitals, expanding services. Watching recent lows at $.36, we're monitoring for the stock to establish a bottom base, anticipating a potential bounce. Our attention is on the first resistance level at $.46, waiting for a break and sustained hold.

--

Aslan Pharmaceuticals Ltd. (NASDAQ: ASLN) - The company ended the week up 15% at $.57. ASLAN is conducting the Phase 2 TREK-DX study on eblasakimab for dupilumab-experienced, moderate-to-severe atopic dermatitis patients. Given the challenges with current treatments, the study aims to address the sizable patient population lacking safe, long-term options. TREK-DX criteria have been updated based on TREK-AD findings, with US recruitment underway and European sites expected in H1 2024. ASLAN plans an early 2024 update on the expected topline readout. Additionally, the company is actively seeking partners following the successful TREK-AD Phase 2b study. We're monitoring support at $.50, watching for a resistance break at $.65, and staying alert for company updates.

--

U Power Limited (NASDAQ: UCAR) - Closing last week 5% higher at $.2499, the company rebounded from 52-week lows of $.17. They recently concluded a follow-on offering, selling 10,000,000 units at $1.20 each, including an ordinary share and Series A and B warrants. In their latest annual filing, the company outlined plans for a service management team to oversee after-sales operations. Service center locations will be selected based on UOTTA-powered EV and battery-swapping station density, authorized dealers, and operational costs. The goal is to establish UOTTA authorized service centers in 8 cities across 6 provinces by the end of 2023. Services for UOTTA-powered EVs will be primarily provided by cooperating auto manufacturers through authorized dealers or service providers. We're closely monitoring for signs of the company's stock reaching a bottom base and watching for a break and hold above the $.26 resistance level.

--

Windtree Therapeutics, Inc. (NASDAQ: WINT) - Closing at $.73 last week, the company announced in November its initiation of the istaroxime program in cardiogenic shock to Phase 3 readiness during the third quarter. CEO Craig Fraser detailed the progress, including advancing two clinical trials and optimizing doses in the SEISMiC Extension Study globally. The company is also moving forward with a study of istaroxime in more severe SCAI Stage C cardiogenic shock patients. This study is expected to begin enrollment in the fourth quarter, contingent on adequate resourcing. Furthermore, this quarter saw advancements in our next-generation dual mechanism SERCA2a activators, including additional research and the U.S. Patent and Trademark Office granting a new composition of matter patent. Beyond various development activities, we are actively involved in business development discussions. This is a busy period for Windtree, and in the upcoming quarters, we anticipate achieving several milestones and events. We will be keeping an eye out for future company updates and a potential resistance break above $.75.

--

Seelos Therapeutics, Inc. (NASDAQ: SEEL) - Closing last week's trading session up 6% at $1.56, the company recently completed an underwritten public offering, including shares of common stock, pre-funded warrants, and accompanying common warrants. Each share of common stock and accompanying common warrant to purchase one share of common stock were sold at a combined price to the public of $1.32 per share of common stock and accompanying common warrant. In September, promising preclinical data for SLS-005 in an Alzheimer's disease non-human primate model were announced. The company is optimistic about the potential of SLS-005 in targeting key biomarkers for Alzheimer's disease. Additionally, top-line data from the SLS-005 registrational Phase II/III trial in ALS as part of the HEALEY ALS Platform Trial led by Harvard Medical School at Massachusetts General Hospital is expected to be released in the fourth quarter of 2023. We will be watching for future updates and a potential break and hold over the $1.70 resistance level.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTime Penny is not a fiduciary by virtue of any person's use of or access to this content.